klionthat.blogg.se

1. #Dr agena obgyn drivers#
2. #Dr agena obgyn driver#
3. #Dr agena obgyn professional#
4. #Dr agena obgyn series#

Agena Davenport-Nicholson is an OBGYN in Atlanta, GA. HealthCare4PPL is your most comprehensive directory of doctors and other health-care professionals in Atlanta GA. Davenport-Nicholson specializes in womens health, caring for the female reproductive system. Wade is a magna cum laude graduate of Spelman College. HealthCare4PPL provides detailed information, including personal overview, history of education and training, specialities, practice locations, affiliated hospitals and more, of 8,982 Medicare-certified and other providers.

#Dr agena obgyn professional#

DR AGENA DAVENPORT NICHOLSON PROFESSIONAL.Cardio vascular diseases account for an estimated 17.5 million people in 2012, representing one third of all global deaths.Īt Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. The World Cancer Report, of World Health Organization predicts 50% rise in cancer rates by 2020 which represents 15 million new cases.

#Dr agena obgyn driver#

The critical demographic driver of the market is the rise in incidence of cancer and other diseases coupled with growing risk factors such as tobacco use, infections such as hepatitis, human papillomavirus (HPV) etc., exposure to ionizing radiation and others. Further real time molecular assessment afforded by liquid biopsy allows designing treatment strategies based on the disease progression. For instance Pathway Genomics and Guardant360 offered liquid biopsy test for cancer at $299 and $5,800 respectively. However liquid biopsy tests are available for less than 6000 USD. dollars, which may increase due to high failure rate of approximately 25%. Tissue biopsies cost around $15,000 to $60,000 U.S. Tissue biopsy has drawbacks such as low detection rate, is expensive and needs approximately 30 days compared to 12 days for liquid biopsy.

#Dr agena obgyn drivers#

The clinical drivers of the market include painless and non-invasive technique, early high precision detection of diseases. Sample – blood, urine and others.Įnd Users – hospitals and laboratories, academic and research centers and others. To give an accurate assessment of the differential potential of the market the report is divided into segments such as biomarker type, application, end users and regions.īiomarker type – circulating tumor cells (CtCs), extracellular vehicles (EVS), circulating tumor DNA (CtDNA), and other biomarker.Īpplication – reproductive health, cancer therapeutic application, and other therapeutic application. The prominent players in the global liquid biopsy market are Guardant Health, Inc., Agena Bioscience Inc., Trovagene Inc., Circulogene Theranostics, Admera Health, RainDance Technologies, Biocept, Inc., Exosome Diagnostics and others. Vascular diseases such as lung cancer, cardiovascular diseases are expected to result in impressive growth. He further estimated lend and lease agreements would benefit both the players and clients, as it will relieve clients of paying a large upfront sum, which it allows the companies a steady revenue and beat competition from other players. Suhail Noolkar, researcher at Market Research Future. The high cost of installation and maintenance of liquid biopsy is a deterrent especially for smaller hospitals which do not possess the buying power says Mr. Lend and lease business model is expected to deliver faster market adoption.

#Dr agena obgyn series#

GRAIL diagnostics raised approximate USD 900 million in a series of financing rounds which is estimated to double in the next stage of rounds.īusiness models are as important as the test itself! For example, Exact Sciences generated an approximate 150 % increase over its 2015 revenues, on account of excellent performance and faster market uptake of its colorectal cancer test Cologuard. The liquid biopsy industry has generated spectacular results culminating in large startup funding. Spectacular revenue growths attracting startup funding The global liquid biopsy market is anticipated to generate USD 1.7 billion by 2022, and growing by a rocking CAGR of 28%. for the detection of diseases such as cancer, cardiovascular, and other ailments. Liquid biopsy provides a non-invasive test using liquid samples such as blood, urine, etc. A liquid biopsy is a diagnostic application occurring from the advances in human genome sequencing and molecular biomarkers.